Abstract:
:The aim of this study was to evaluate S100B in bone marrow (BM) plasma from malignant melanoma patients. BM aspirates and peripheral blood (PB) plasma from 56 patients and BM aspirates from 29 healthy volunteers were collected. S100B was measured using an immune radiometric assay, which is a two-site sandwich assay based on monoclonal antibodies recognizing the beta-subunit. In the control population, the median S100B level in BM plasma was 9.0 microg/l (26 women and three men), an unexpectedly high value compared with the median S100B level in PB<0.05 microg/l. S100B levels in BM seems to be sex dependent. Median S100B levels in samples taken from male melanoma patients was 26.7 microg/l in contrast to 9.3 microg/l in female patients (Mann-Whitney P<0.002). The elevated BM S100B in melanoma patients could not be explained by presence of melanoma cells in the BM, as the values also were increased to the same extent in patients with no detectable BM metastases. In attempts to identify the source of S100B in BM, cytospins from five patients with high S100B values were stained, but none of the BM cells stained positive. S100B levels in PB were dependent on the stage of melanoma disease and there was a significant shorter survival time in the group of patients with elevated S100B compared with the group with normal S100B values, (log rank test: P=0.04). In BM taken from melanoma patients, however, there were no association between S100B levels and survival. The median S100B level in BM aspirates from healthy female volunteers and BM samples from female melanoma patients were 8.1 and 9.3 microg/l both manifold higher than the cut-off value for S100B in PB (0.2 microg/l). The median S100B in the samples taken from male melanoma patients was nearly three times higher than in the female patients. Unlike S100B in PB, S100B in BM demonstrated no prognostic value. The explanation for the unexpected high S100B in BM remains elusive.
journal_name
Melanoma Resjournal_title
Melanoma researchauthors
Faye RS,Paus E,Maelandsmo GM,Berner A,Høifødt HK,Fodstad Ø,Aamdal Sdoi
10.1097/CMR.0b013e3282f623d9subject
Has Abstractpub_date
2008-04-01 00:00:00pages
134-40issue
2eissn
0960-8931issn
1473-5636pii
00008390-200804000-00008journal_volume
18pub_type
杂志文章abstract::Prognostic blood biomarkers for patients with uveal melanoma have not been identified. Tumor monosomy-3 is strongly associated with the development of metastatic disease. Tumor expression of human leukocyte antigen class I molecules and insulin-like growth factor (IGF)-1 receptor has also been associated with the deve...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/CMR.0b013e32835b7154
更新日期:2013-02-01 00:00:00
abstract::Melanomas are promising targets for immunotherapy, as they express a number of tissue-specific antigens against which immune responses can be elicited. We have previously described transgenic mice in which malignant cutaneous melanomas are produced. The 1042 melanoma cell line, derived from a primary melanoma in one o...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/00008390-200412000-00019
更新日期:2004-12-01 00:00:00
abstract::Between 1983 and 1990, 59 patients with malignant melanoma were retrospectively reviewed to assess the safety, efficacy and the maximal tolerated dose of cisplatin used in hyperthermic isolated limb perfusion. The median follow-up was 29 months (range 3-54 months). The local recurrence rate was 12% in Stage I, 33% in ...
journal_title:Melanoma research
pub_type: 临床试验,杂志文章
doi:10.1097/00008390-199104000-00007
更新日期:1991-04-01 00:00:00
abstract::Between 1983 and 1992, 21 patients with extremity stage IIIA or IIIAB melanoma underwent hyperthermic isolation limb perfusion (HILP) with cisplatin in dosages varying from 26 to 237 mg/m2 as part of a pharmacokinetics and maximum-tolerated dose study. Extremity temperatures were up to 40 degrees C and the pH was cont...
journal_title:Melanoma research
pub_type: 临床试验,杂志文章
doi:
更新日期:1994-03-01 00:00:00
abstract::Our previous in vivo studies indicated that a phenolic thioether amine (PTEA), 4-S-cysteaminylphenol (CAP), selectively disintegrates melanocytes of black hair and skin, and inhibits the growth of murine and human malignant melanomas. To elucidate the mechanism of the in vivo melanocytotoxicity and anti-melanoma effec...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/00008390-199211000-00002
更新日期:1992-11-01 00:00:00
abstract::Melanogenesis appears to be a unique target to develop anti-tumour agents specific for malignant melanoma. Among the anti-melanoma compounds that we have examined, 4-S-cysteaminylphenol (4-S-CAP), a phenolic amine, was found to have the most promising anti-melanoma effects. To further improve the efficacy as anti-mela...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/00008390-200404000-00006
更新日期:2004-04-01 00:00:00
abstract::Reversible oxidation sensitivity of N-Oct-3 DNA binding activity was seen when melanoma extracts and recombinant Brn-2 protein were treated with a variety of metals, hydrogen peroxide and the cysteine disulphide bond forming agent diamide. Western blot analysis of diamide-oxidized N-Oct-3 protein indicated that this w...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/00008390-199802000-00002
更新日期:1998-02-01 00:00:00
abstract::Appropriate margins of excision for melanoma have been well defined on the basis of prospective clinical trials. Various factors may result in a discrepancy between the intended clinical margin and the pathologic margin ex vivo, however, making it difficult to determine whether adequate excision margins have been obta...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/00008390-200512000-00009
更新日期:2005-12-01 00:00:00
abstract::Identifying groups of subjects at high risk for the development of melanoma is crucial for the early diagnosis of curable tumours. In the present study, we performed a skin examination in a group of 63 patients followed up after treatment of germ cell tumours (GCTs) who were referred to the dermatologist for multiple ...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/00008390-200104000-00005
更新日期:2001-04-01 00:00:00
abstract::Intercellular adhesion molecule (ICAM)-1 and mucin isotype MUC18 were originally identified as melanoma progression antigens by monoclonal antibodies (MAb) generated in a search for molecules expressed by melanomas but not detectable on benign naevi. As MAb detect single epitopes whose accessibility may be modulated, ...
journal_title:Melanoma research
pub_type: 杂志文章
doi:
更新日期:1997-08-01 00:00:00
abstract::Selective sentinel lymph node (SLN) dissection is widely used in the management of cutaneous melanoma patients without clinical evidence of nodal metastases. A series of 274 consecutive melanoma patients who underwent melanoma primary excision and SLN mapping at our institutions since 1998, and were thereafter followe...
journal_title:Melanoma research
pub_type: 临床试验,杂志文章
doi:10.1097/00008390-200404000-00016
更新日期:2004-04-01 00:00:00
abstract::One of the principal applications of tumour markers is the early detection of recurrent disease in the follow-up of patients. In the study described here, we compared the usefulness of two serum markers for melanoma, 5-S-cysteinyldopa (5-S-CD) and melanoma inhibitory activity (MIA), in the monitoring of postsurgical m...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/00008390-200208000-00003
更新日期:2002-08-01 00:00:00
abstract::The goal of this study was to determine the effect of oral melatonin in divided doses on plasma melatonin levels in patients with metastatic melanoma. Hourly blood samples were obtained from five patients for 24 h prior to melatonin administration and for 24 h during oral administration of melatonin, 50 mg every 4 h. ...
journal_title:Melanoma research
pub_type: 临床试验,杂志文章
doi:10.1097/00008390-199402000-00009
更新日期:1994-02-01 00:00:00
abstract::Cerebral metastases from melanoma are correlated with a poor prognosis. Temozolomide is an oral alkylating agent that can cross the blood-brain barrier and in phase II and III trials, patients with advanced metastatic melanoma achieved overall response rates of 13 to 21%. The present study evaluated the efficacy and t...
journal_title:Melanoma research
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1097/01.cmr.0000136707.60108.ab
更新日期:2004-08-01 00:00:00
abstract::Cellular senescence is a major barricade on the path of cancer development, yet proteins secreted from senescent cells exert complex and often discordant effects on subsequent cancer evolution. Somatic genome alternations driving the formation of nevi and melanoma are efficient inducers of cellular senescence. Melanoc...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/CMR.0000000000000671
更新日期:2020-08-01 00:00:00
abstract::CDKN2A is thought to be the main candidate gene for melanoma susceptibility. Deletion or mutations in the CDKN2A gene may produce an imbalance between functional p16 and cyclin D, causing abnormal cell growth. We here describe a novel mutation consisting of a 1 bp deletion at nucleotide position 201 (codon 67) (CACGGc...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/00008390-200110000-00002
更新日期:2001-10-01 00:00:00
abstract::Electrochemotherapy (ECT), chemotherapy administered in combination with electric fields, has the potential to be an effective localized treatment for cutaneous malignancies. Bleomycin's cytotoxicity was enhanced by exposing tumour cells to electrical fields following intravenous injection of the chemotherapeutic agen...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/00008390-199702000-00003
更新日期:1997-02-01 00:00:00
abstract::During the initiation and progression of malignant melanoma a series of genetic events accumulate, including alterations of chromosome 11q. Recently, an important tumour suppressor gene, the multiple endocrine neoplasia type 1 (MEN1) gene, has been mapped on 11q13 and has been cloned. To assess whether the MEN1 region...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/00008390-199906000-00006
更新日期:1999-06-01 00:00:00
abstract::The cell surface glycoprotein MUC18 was originally identified as a progression associated antigen in melanoma. MUC18 is expressed most strongly on metastatic lesions and advanced primary tumours and is only rarely detected in benign lesions. cDNA cloning revealed MUC18 to be a novel member of the immunoglobulin superf...
journal_title:Melanoma research
pub_type: 杂志文章,评审
doi:10.1097/00008390-199310000-00006
更新日期:1993-10-01 00:00:00
abstract::The objective of this study was to identify novel tumor-suppressor genes in melanoma, using an integrative genomic approach. Data from: (i) earlier reports of DNA loss and gain in malignant melanoma accompanied by comparative genomic hybridization high-definition array data of the entire human genome; (ii) microarray ...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/CMR.0b013e328344a003
更新日期:2011-08-01 00:00:00
abstract::Little population-based data has been published about skin cancers in children and young adults. In this study, 200 cases of melanoma and non-melanoma skin cancers diagnosed under 25 years of age in the North of England from 1968-1995 were obtained from the Northern Region Young Persons' Malignant Disease Registry. Th...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/01.cmr.0000056259.56735.eb
更新日期:2003-08-01 00:00:00
abstract::Familial atypical multiple mole-melanoma (FAMMM) syndrome is characterized by the familial occurrence of malignant melanoma of the skin in combination with multiple atypical precursor naevi. In the present study we performed linkage analysis in seven Dutch FAMMM families to define the relationship between the ultimate...
journal_title:Melanoma research
pub_type: 杂志文章
doi:
更新日期:1993-08-01 00:00:00
abstract::Proteomics provides a powerful approach for screening alterations in protein expression and post-translational modification associated with particular human diseases. In this study, the analysis of protein expression was focused on malignant melanoma in order to determine the candidate genes involved in tumour progres...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/00008390-200508000-00002
更新日期:2005-08-01 00:00:00
abstract::The growth rate (GR) of melanomas is not uniform. A fast-growing subtype has been identified and seems to have a role in the stabilization of the mortality rates because of melanoma. To examine features associated with fast-growing melanomas (FGMs) and to determine the relationship between the GR and well-recognized p...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/CMR.0b013e328342f312
更新日期:2011-04-01 00:00:00
abstract::Immunotherapy with anti-programmed cell death-1 (PD-1) agents is an effective treatment for metastatic melanoma. Octogenarians and nonagenarians represent a significant cohort of melanoma patients. This multicenter retrospective analysis enrolled 499 patients treated with nivolumab or pembrolizumab. Seventy-three pati...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/CMR.0000000000000705
更新日期:2021-02-01 00:00:00
abstract::BRAF mutations are found in ~50% of metastatic melanomas, most commonly in codon V600. Vemurafenib improves progression-free survival and overall survival in patients with advanced BRAF-mutated melanoma. The results of a descriptive study evaluating vemurafenib in patients with advanced melanoma harbouring BRAF mutati...
journal_title:Melanoma research
pub_type: 杂志文章,多中心研究
doi:10.1097/CMR.0000000000000398
更新日期:2017-12-01 00:00:00
abstract::We have observed that an early increase in the CD4+/CD8+ ratio of metastatic melanoma patients during chemoimmunotherapy is the most favourable independent prognostic factor. In this study, 87 patients with metastatic melanoma were monitored for peripheral blood lymphocyte subsets (CD4+ and CD8+) before and during che...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/00008390-200412000-00009
更新日期:2004-12-01 00:00:00
abstract::Cutaneous malignant melanoma is one of the most common and aggressive forms of human cancers and has a poor prognosis. Activation of signal transducer and activator of transcription 3 (STAT3) has been found in several human cancers and is thought to correlate aggressive disease and poor response. In this study, we inv...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/CMR.0b013e32834acc37
更新日期:2011-12-01 00:00:00
abstract::Selective inhibition of the mutant BRAF protein is a highly promising therapeutic approach for melanoma patients carrying the BRAF mutation. Despite the remarkable clinical response, most patients develop resistance and experience tumour regrowth. To clarify the molecular background of BRAF inhibitor resistance, we ge...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/CMR.0000000000000588
更新日期:2019-08-01 00:00:00
abstract::The management of melanoma brain metastases (MBM) includes different therapeutic modalities, such as surgery, radiotherapy and chemotherapy. Despite the choice of treatments, survival remains poor, exceeding 1 year only in patients with solitary metastases and absence of extracranial disease. A total of 115 consecutiv...
journal_title:Melanoma research
pub_type: 杂志文章
doi:10.1097/CMR.0000000000000029
更新日期:2014-02-01 00:00:00